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Bile duct tumor thrombus (BDTT) of a hepatocellular carcinoma (HCC) is a rare entity which was found
microscopically in 1 to 9.2% of the resected specimen.
A 54-year-old male was found to have a 65-mm hepatocellular carcinoma in segment VI of the liver with a huge
intrahepatic bile duct tumor thrombus. As the main trunk of the posterior segment branched from the left bile
duct, the BDTT of the posterior branch extended to the common bile duct via the left bile duct. When the
posterior segment was resected along with the left lobe, the estimated remnant liver volume was less than 30%.
Therefore, the patient underwent extended posterior segmentectomy with choledochotomy and all of the BDTT
was removed via the common bile duct.
Three months later, his serum bilirubin (6.63 mg/dL) and des-gamma-carboxy prothrombin (410 ng/mL) were re-
elevated due to recurrent BDTT. A well-enhanced BDTT was observed by computed tomography (CT) at the left
bile duct. Transarterial chemotherapy with cisplatin was scheduled, followed by endoscopic retrograde bile duct
drainage. After four sessions of this chemotherapy, the BDTT had vanished and the tumor marker was decreased to
within the normal range. The patient was stably treated with this regimen and has remained recurrence-free for five
years.
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Bile duct tumor thrombus (BDTT) of a hepatocellular
carcinoma (HCC) is a rare entity which was found
microscopically in 1 to 9.2% of the resected specimen of
this male patient. An icteric hepatoma was found
obstructing the common bile duct (CBD). The prognosis
for BDTT with palliative treatment was poor, about 3 to
13 months, and with no treatment was three months or
less [1,2]. However, there was a chance for long time
survival if the BDTT was surgically removed with the
primary lesion [3,4].
The available treatment options for palliative treat-
ment are transarterial chemoembolization, radiation and
a combination of these modalities. But the treatment* Correspondence: yamazaki-nmed@umin.ac.jp
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reproduction in any medium, provided the oreffects are limited because the tumor is usually wide-
spread in the liver.
We experienced a case in which recurrent BDTT was
put into complete remission by transarterial chemotherapy
(TAC) with cisplatin. TAC with cisplatin may be one of the
additional options following a palliative operation.Case report
A 55-year-old man was admitted to our department for
treatment of a 65 mm HCC in segment VI of the liver.
An HCC involving the portal vein and bile duct tumor
thrombus were found on abdominal computed tomog-
raphy (CT) (Figure 1A). The patient had severe liver cir-
rhosis due to a hepatitis B viral infection. The laboratory
results showed that liver enzyme and serum alpha-
fetoprotein (2.2 ng/mL) were within the normal ranges
whereas des-gamma-carboxy prothrombin (DCP) (410
ng/mL) was increased.td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 (A) A well enhanced tumor thrombus of a HCC involving the portal vein and bile duct dilatation were found (arrow head).
(B) The intraoperative chorengiography revealed that bile duct tumor thrombus was extended from the posterior bile duct to the CBD via
the left bile duct (arrow head). (C) The well enhanced recurrent bile duct tumor thrombus was found in the common bile duct
(arrow head). (D) After a total of four treatments of TAC with cisplatin, the BDTT was observed with magnetic resonance
cholangiopancreatography to be in complete remission.
Ebara et al. World Journal of Surgical Oncology 2013, 11:78 Page 2 of 3
http://www.wjso.com/content/11/1/78During the operation, the intraoperative cholangiog-
raphy confirmed that the posterior bile duct was
branched from the left bile duct and the BDTT extended
to the CBD via the left bile duct (Figure 1B). The
remnant liver was less than 30% of the whole liver vo-
lume when the left lobe was resected along with the pos-
terior segment. Therefore, the patient underwent
extended resection of the posterior segment with
choledochotomy to remove the BDTT in the left lobe. A
massive infiltration of BDTT was found in the resected
specimen.
Three months later, the patient was found to have obs-
tacle jaundice due to recurrent BDTT. The serum biliru-
bin (6.63 mg/dL) and DCP (178 ng/mL) were increased
in the laboratory data. Well enhanced BDTT in the ar-
terial phase was confirmed with angiography (Figure 1C).
Therefore, we planned trans-arterial chemotherapy
followed by endoscopic retrograde bile duct drainage
(Flexima, Boston Scientifics, Boston, MA, USA). A total
of 70 mg/body of cisplatin powder (IA Call, Kaken,
Tokyo, Japan) was infused through the common hepatic
artery. After a total of four treatments with TAC with
cisplatin, the BDTT was not observed on magneticresonance cholangiopancreatography (Figure 1D) and
the tumor markers were decreased to within normal
range. TAC was discontinued but the patient remains in
good condition without any new recurrence five years
after the liver resection.Discussion
The median survival time in patients with BDTT is more
than two to three years when the primary lesion with
BDTT is completely resected [1-4]. In contrast, the me-
dian survival following the palliative operation is less
than six months and with the biliary drainage alone is
three months [5,6]. Thus, it is necessary to resect the
primary lesion. However, most cases of BDTT are not
good candidates for surgery because the primary lesion
is advanced or BDTT is widely spread in the liver. Most
cases present with liver insufficiency and contraindica-
tion for targeted therapy such as Sorafenib. While there
are some treatment options for portal venous tumor
thrombus caused by HCC, radiation and transarterial
chemoembolization therapy enable the survival time to
be extended in some studies [7,8].
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median survival time was 13.4 months (range 8 to 26
months) [5,6]. The use of TAC with cisplatin in
unresectable or recurrent HCC has been demonstrated
recently [9-11]. This treatment regimen might be the
best additional treatment for BDTT because the
thrombus is fed by arterial blood [5-8]. Moreover, TAC
enables to perform when the remnant liver was small or
when patients have poor liver function. For our patient,
we performed a total of four treatments of TAC with cis-
platin and the BDTT subsided and tumor markers were
decreased to normal. Due to the design of the study case
series, we could not advocate TAC as a first treatment
option in all BDTT cases.
The proposed treatment for BDTT is complete resec-
tion of the primary lesion with BDTT. However, our
case suggested that TAC with cisplatin may have the po-
tential to be an effective treatment option for BDTT in a
palliative case.
Conclusions
This case report suggested that transarterial chemothe-
rapy with cisplatin may have the potential to be an ef-
fective treatment option for BDTT.
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